NSABP-C-08

Regimen

Experimental
Bevacizumab 5 mg/kg Q2W × 52 weeks + mFOLFOX6 × 26 weeks
Control
mFOLFOX6 × 26 weeks alone

Population

Stage II or III colon cancer after curative resection (N=2,672), adjuvant bevacizumab added to mFOLFOX6.

Key finding

NEGATIVE: 3-year DFS 77.4% (bev+FOLFOX) vs 75.5% (FOLFOX alone), HR 0.89, P=.15. Transient DFS benefit during bevacizumab exposure (HR 0.61 at 15-month landmark) that reverses after cessation (HR 1.22). No recommendation for bevacizumab in adjuvant colon.

Source: PMID 20940184

Timeline

    Guideline citations

    • NCCN Colon (p.103)